Drug Approval | July 11, 2025
FDA accepts new drug application for Merck’s Doravirine/Islatravir
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The company has confirmed that the deceased are 39
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Subscribe To Our Newsletter & Stay Updated
